Purinergic P2X receptor 7 (P2X7R) inhibition induced cytotoxicity in glioblastoma.

ABSTRACT: Glioblastoma is the most common and aggressive form of primary brain cancer with a median survival of 15 months from diagnosis. The purinergic receptor P2X7 (P2X7R) is a regulator of several cell signalling pathways, and its expression is upregulated in glioblastoma. This study examined the expression and function of P2X7R in a human glioblastoma cell line, U251. We used a pharmacological antagonist of P2X7R, AZ10606120, to inhibit receptor function and delineate downstream consequences of receptor inhibition. Using RNA sequencing we demonstrated that P2X7R was expressed in the U251 cell line, harbouring both Y155H (Tyr to His) and E496A (Glu to Ala) single nucleotide polymorphism (SNP) mutations. The receptors functionality - namely its pore and channel conductance states were intact. Inh

SUBMITTER: Drill M 

PROVIDER: S-EPMC12440200 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature